gdc
FDA Approvals, News & UpdatesMultiple Myeloma

Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma

In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
October 2020 Vol 6 No 5

In August 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a BCMA-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received 4 or more previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug. Blenrep is the first BCMA antibody, representing a new approach to the treatment of multiple myeloma.

The FDA approved Blenrep based on an open-label, multicenter clinical trial in which patients received Blenrep therapy by intravenous infusion once every 3 weeks, until their disease progressed or if they had unacceptable side effects.

The efficacy of Blenrep was established based on the overall response rate to treatment and the duration of the response. The overall response rate was 31%, and 73% of those who had a response to therapy with Blenrep had a response lasting 6 months or longer.

The most common side effects associated with Blenrep therapy included keratopathy, decreased visual acuity, nausea, blurred vision, pyrexia, infusion-related reactions, and fatigue.

Blenrep is associated with a risk for serious vision-related side effects.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLung Cancer
Gavreto Second Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions
In September 2020, the FDA approved a second drug for the treatment of patients with lung cancer and RET fusions, improving the treatment options available today for patients with this type of lung cancer.
FDA Approvals, News & UpdatesLung Cancer
Retevmo First Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions
In May 2020, the FDA approved the first drug ever for the treatment of patients with lung cancer and RET fusions, a type of biomarker that can lead to lung cancer and requires specific drug therapy.
FDA Approvals, News & UpdatesLymphoma
FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In July 2020, the FDA approved Monjuvi as a new treatment option for patients with diffuse large B-cell lymphoma whose disease progressed after receiving other therapies.
FDA Approvals, News & UpdatesLymphoma
Tecartus First Gene Therapy FDA Approved for Patients with Mantle-Cell Lymphoma
The FDA approved Tecartus as the first gene therapy (or CAR T-cell therapy) for patients with mantle-cell lymphoma, a rare type of non-Hodgkin lymphoma, that progressed after previous therapies.
Last modified: November 10, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country